Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are recently introduced drug classes for the treatment of type 2 diabetes (T2D). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.